Lovastatin decreases acute mucosal inflammation via 15-epi-lipoxin A 4

96Citations
Citations of this article
50Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The widespread use of statins for hypercholesterolemia has uncovered pleiotropic anti-inflammatory properties that were unexpected based on the drugs' original design; yet, mechanisms for these protective actions remain uncertain. In this study lovastatin triggered biosynthesis of the anti-inflammatory and pro-resolving mediator 15-epi-lipoxin A 4 (15-epi-LXA 4). During interactions between human neutrophils and airway epithelial cells, the statin-induced increase in 15-epi-LXA 4 was associated with increased 14,15-epoxyeicosatrienoic acid (14,15-EET) generation. When added to activated neutrophils, 14,15-EET enhanced 15-epi-LXA 4 biosynthesis. In a murine model of airway mucosal injury and inflammation, lovastatin increased 15-epi-LXA 4 formation in vivo and markedly decreased acute lung inflammation. Administration of 15-epi-LXA 4 also inhibited lung inflammation in an additive manner with lovastatin. Together, these results indicate that statin-triggered 15-epi-LXA 4 generation during human leukocyte-airway epithelial cell interactions is an endogenous mechanism for statin-mediated tissue protection at mucosal surfaces that may also be relevant in the statins' ability to stimulate the resolution of inflammation. © 2010 Society for Mucosal Immunology.

Cite

CITATION STYLE

APA

Planagumà, A., Pfeffer, M. A., Rubin, G., Croze, R., Uddin, M., Serhan, C. N., & Levy, B. D. (2010). Lovastatin decreases acute mucosal inflammation via 15-epi-lipoxin A 4. Mucosal Immunology, 3(3), 270–279. https://doi.org/10.1038/mi.2009.141

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free